The Multiple Myeloma Research

“Kathy giusti, founder & former chief mission officer, and karen andrews, board member have a family relationship.”

“The form 990 is first reviewed with the ceo of the foundation. Once reviewed with the ceo, the form 990 is emailed to each board member. Each board member reviews the form 990 and if any questions arise, they are communicated to the foundation and addressed. After all questions are addressed, the form 990 is submitted to the irs.”

“The organization's conflict of interest policy applies to any director, officer, or member of a standing or advisory committee with powers delegated by the mmrf board of directors who may have a direct or indirect financial interest (i.e. "interested person"). Duty to disclose a potential conflict of interest: any interested person must disclose the existence of his or her financial interest to the board or audit committee and must be given the opportunity to disclose all material facts to the board, members of the audit committee and all members of any committee considering the proposed contract or transaction. Determining whether a conflict of interest exists: after disclosure of the financial interest and all material facts, and after any discussion with the interested person, the interested person shall leave the board or audit committee meeting while the determination of a conflict of interest is discussed and voted upon. The remaining board or audit committee members, as applicable, shall decide if a conflict of interest exists. Procedures for addressing the conflict of interest: i. An interested person may make a presentation at the board or audit committee meeting, but after such presentation, he or she shall leave the meeting during the discussion of, and the vote on, the contract or transaction that result in the conflict of interest. Ii. The chair of the board or chairperson of the audit committee shall, if appropriate, appoint a disinterested person or appoint or establish an advisory committee to investigate alternatives to the proposed contract or transaction. After exercising due diligence, the board or the audit committee shall take all reasonable steps to determine whether the mmrf can obtain a more advantageous contract or transaction with reasonable efforts from a person or entity that would not give rise to a conflict of interest. If a more advantageous contract or transaction is not reasonably attainable under circumstances that would not give rise to a conflict of interest, the board or audit committee shall determine by a majority vote, but not less than two, of the disinterested directors or members thereof whether the contract or transaction is in the mmrf's best interest and is fair and reasonable to the mmrf; provided, however, if such contract or transaction is approved by disinterested directors who do not satisfy a quorum or voting requirement applicable to the authorization of the action by reason of the mmrf's certificate of incorporation, bylaws or a provision of law, the action must be independently approved by such interested and disinterested directors as satisfy the applicable quorum or voting requirement. Violation of the conflicts of interest policy: iii. If the board or audit committee has reasonable cause to believe that a director, officer or committee member has failed to disclose actual or possible conflicts of interest, it shall inform such person of the basis for such belief and afford such person an opportunity to explain the alleged failure to disclose. If, after hearing the response of the director, officer or committee member and making such further investigation as may be warranted in the circumstances, the board or audit committee determines that such person has in fact failed to disclose an actual or possible conflict of interest, the board or audit committee, as applicable, shall take appropriate disciplinary and corrective action.”

“All senior positions and their compensation are reviewed and approved by the board of directors. Compensation is benchmarked against other 501(c)(3)'s, research organizations, third party compensation database and then reviewed by the audit and finance committee. The compensation approval is documented in the minutes by the committee. This process was last undertaken in 2024.”

“Financial statements, governing documents, conflict of interest policy, form 990 and form 1023 are made available for public viewing upon written request at mmrf's headquarters. Form 990 and audited financial statements are also available at the organization's website: www.themmrf.org the form 990 is also available on www.guidestar.org, www.charitynavigator.org, and other similar websites.”

“Mmrf accomplishments for 2024 the multiple myeloma research foundation, inc. And its wholly owned subsidiaries, the multiple myeloma research consortium, llc ("mmrc") and myeloma investment fund, llc ("mif"), collectively referred to as "the mmrf," is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. The mmrf drives the development and delivery of next-generation therapies, leverages data to identify optimal and more personalized treatment approaches and empowers myeloma patients and the broader community with information and resources to extend their lives. Central to the mmrf's mission is its commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances they pursue. Since its incorporation on january 13, 1998, the mmrf has committed over $600 million for research, opened nearly 100 clinical trials, and helped bring 15+ fda approved therapies to market, which have tripled the life expectancy of myeloma patients. In 2024 the mmrf invested $30m in urgent research programs and support services for myeloma patients. Through the myeloma investment fund (mif), we invested in five early-stage biotech companies pursuing innovative, potentially game-changing treatments for myeloma. We launched the groundbreaking horizon clinical trials program, enrolling the first patient back in november. As part of our commitment to health equity, we appointed a chief diversity officer and introduced several initiatives aimed at ensuring our clinical studies reflect the real-world u.s. Myeloma populationwith a goal of enrolling at least 20% black and 15% hispanic participants.”

“The multiple myeloma research foundation (mmrf) is the largest nonprofit in the world solely focused on accelerating acurefor multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the mmrf has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ fda-approved therapies to market, which have tripled the life expectancy of myeloma patients.”

“Consulting: program service expenses 1,393,127. Management and general expenses 70,877. Fundraising expenses 690,286. Total expenses 2,154,290. Medical professionals: program service expenses 2,054,597. Management and general expenses 0. Fundraising expenses 209,819. Total expenses 2,264,416. Recruiting costs & temporary help: program service expenses 189,402. Management and general expenses 24,241. Fundraising expenses 58,097. Total expenses 271,740.”

“Loss on disposal of assets -693,210. Gain on lease termination 152,828.”

“The multiple myeloma research foundation, inc. Audit/finance committee recommends the auditor to the board, and the board appoints the auditor. The board assumes responsibility for the oversight of the audit of its financial statements. The policy for selection and oversight of the independent auditors has not changed since last year.”